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Abstract
Infection is the leading cause of complication after liver 
transplantation, causing morbidity and mortality in the 
first months after surgery. Allograft rejection is medi-
ated through adaptive immunological responses, and 
thus immunosuppressive therapy is necessary after 
transplantation. In this setting, the presence of genetic 
variants of innate immunity receptors may increase the 
risk of post-transplant infection, in comparison with pa-
tients carrying wild-type alleles. Numerous studies have 
investigated the role of genetic variants of innate im-
mune receptors and the risk of complication after liver 
transplantation, but their results are discordant. Toll-
like receptors and mannose-binding lectin are arguably 
the most important studied molecules; however, many 
other receptors could increase the risk of infection after 
transplantation. In this article, we review the published 
studies analyzing the impact of genetic variants in the 
innate immune system on the development of infectious 
complications after liver transplantation. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: After liver transplantation, immunosuppres-
sive therapy is needed to avoid allograft rejection that 
is mainly mediated through adaptive immunological 
responses. In the setting, the existence of genetic vari-
ants of innate immunity receptors may increase the 
risk of post-transplant infections in comparison with 
patients carrying wild-type alleles. This manuscript re-
views the published studies analyzing the influence of 
innate immunity gene variants on the development of 
post-transplant infections and other complications.
Sanclemente G, Moreno A, Navasa M, Lozano F, Cervera C. Ge-
netic variants of innate immune receptors and infections after liver 
transplantation. World J Gastroenterol 2014; 20(32): 11116-11130 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v20/i32/11116.htm  DOI: http://dx.doi.org/10.3748/wjg.v20.
i32.11116
INTRODUCTION
Liver transplantation is the treatment of  choice for 
end-stage liver disease. New developments in surgical 
techniques, medical care, and immunosuppressant thera-
pies have improved both graft and patient survival[1,2]. 
However, infections are still among the main complica-
tions after liver transplantation; it has been estimated 
that up to 80% of  liver recipients will develop at least 
one episode of  infection during the first year after trans-
plantation[3,4]. Although several identifiable clinical risk 
factors are clearly associated with higher risk of  post-
transplant infection[5], variations in the receptors of  the 
innate immune system could play an important role in its 
incidence and severity. 
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Bacteria are the leading cause of  early infection after 
liver transplantation. Both the sources and etiology of  
infection change over time, according to the degree of  
immunosuppression and the presence of  clinical risk fac-
tors. In the first month after transplantation, bacterial in-
fections typically arise from the abdominal cavity, surgical 
wound, intravenous catheters, and the respiratory tract. 
Between the first and the sixth month after transplanta-
tion, the risk of  opportunistic infections is increased 
because of  the higher degree of  immunosuppression. 
After the sixth month, infections are usually community 
acquired and predominantly respiratory and urinary, al-
though cholangitis can occur if  there are strictures in the 
biliary tree[3,6-8]. 
Viral infections after liver transplantation are frequent. 
Herpes simplex virus reactivation can occur early post-
transplantation, typically with orolabial or genital ulcers 
appearing 2-3 wk after transplantation[9]. Herpes zoster 
virus reactivation occurs in around 10% of  solid organ 
transplant recipients, but is mostly limited to dermal 
manifestations. The first year after transplantation poses 
the greatest risk of  Epstein-Barr virus (EBV), which may 
be associated with lymphoproliferative disease[10]. Cyto-
megalovirus (CMV) can cause direct disease, manifested 
as fever, bone marrow suppression, and organ invasion. 
In addition, due to its ability to induce immunomodula-
tion, CMV can cause indirect effects; these include fa-
voring the development of  opportunistic infections and 
hepatitis C virus (HCV) recurrence, EBV-associated lym-
phoproliferative disease, acute rejection, chronic allograft 
dysfunction, vascular and hepatic artery thrombosis, and 
ultimately, allograft failure and death[11-15]. Although sev-
eral risk factors for CMV infection have been described, 
the most important is donor-recipient serology mismatch 
(donor positive/recipient negative) at the time of  trans-
plantation. Also, certain immunosuppressive therapies 
(lymphocyte-depleting drugs such as anti-thymocyte 
globulin) and acute allograft rejection are associated with 
a higher risk of  CMV infection[11,16]. Other viral infections 
after transplantation, such as human herpesvirus 6 and 
7, are less frequent and usually asymptomatic. However, 
they can also produce pneumonitis, encephalitis, hepatitis, 
and bone marrow suppression. Human herpesvirus 8 is 
also associated with Kaposi sarcoma[17]. 
Fungal infections represent one of  the most life-
threatening complications after liver transplantation. Al-
though its incidence has declined (5%-30% depending on 
the series), they continue to be associated with high mor-
tality. Candida species are the most frequent invasive fungi, 
followed by Aspergillus species[18]. Most invasive fungal 
infections (IFIs) occur early after transplantation, mainly 
during the first 3 mo. Multiple risk factors exist for IFI, 
such as pre-transplant comorbidity, surgical complications, 
and morbid post-transplant course[18-21]. Pre-transplant 
comorbidity includes a high Model for End-Stage Liver 
Disease score, acute hepatic insufficiency, pretransplant 
renal insufficiency, prolonged preoperative hospitalization, 
previous use of  broad-spectrum antibiotics, fungal colo-
nization, and re-transplantation[18-21]. Surgical complica-
tions include long surgical time, high intraoperative use of  
blood products, and choledochojejunostomy anastomosis, 
while a morbid post-transplant course involves dialysis 
requirement, acute rejection, CMV infection, early graft 
failure, and reoperation after transplantation[18-21]. 
The correct integrity and functionality of  the host’s 
immune system is a key pathogenic factor for the oc-
currence and severity of  post-transplant infection. The 
innate immune system is the first line of  defence against 
invasion by pathogens. It comprises cellular components 
[neutrophils, macrophages, dendritic cells, and natural 
killer (NK) cells] and molecular mediators (cell receptors, 
complement system, cytokines, and chemokines). Innate 
immune responses occur rapidly, with limited specificity 
and an inability to generate immunological memory. In-
nate immune receptors, also named pattern-recognition 
receptors (PRRs), are expressed by effector immune cells 
as either soluble or membrane-bound proteins. They rec-
ognize conserved structures, named pathogen-associated 
molecular patterns (PAMPs), which are broadly distrib-
uted among different types of  microbes but absent from 
host cells, and are essential for microbial survival and 
pathogenicity. The binding of  microorganisms by PRRs 
triggers intracellular signal pathways that culminate in the 
synthesis of  cytokines and chemokines. This then causes 
inflammation, and induces the maturation and migra-
tion of  antigen-presenting cells to secondary lymphoid 
tissues, where they activate adaptive responses. In con-
trast to the innate immune system, the adaptive immune 
system is slower to activate, but achieves highly specific 
immune responses based on immunological memory. 
Adaptive immunity is mainly mediated by T and B 
lymphocytes, which express antigen-specific receptors 
generated by genetic recombination during lymphocyte 
development. The repertoire of  lymphocyte receptors is 
broad enough to recognize virtually any antigen. After 
the first exposure to an antigen, it takes up to 3-5 d to 
produce sufficient numbers of  antigen-specific T and B 
cell clones, while the innate immune system generates 
a protective inflammatory response within minutes of  
pathogen exposure[22-26]. 
Acute cellular and humoral allograft rejection is medi-
ated by T and B cells respectively[27-29]. Patients undergo-
ing solid organ transplantation must receive immunosup-
pressive therapy, which predominantly alters the adaptive 
immune response by blocking lymphocyte activation sig-
naling pathways, depleting lymphocytes, or diverting lym-
phocyte traffic[25,30,31]. In these circumstances, the innate 
immune response predominates in the defence against 
infection. 
Gene polymorphisms, typically single nucleotide 
polymorphisms (SNPs), are common, occurring in > 
1% of  the general population. SNPs may alter the amino 
acid sequence, affect promoter characteristics, or may be 
completely “silent”. Several SNPs have been described 
in relation to the genes encoding immune recognition[32]. 
Indeed, previous studies have found higher infection 
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rates in populations with SNPs in genes encoding innate 
immunity components[32-36]. Table 1 summarize the most 
relevant studies about innate immunity gene variants and 
risk of  post-transplant liver infections.
INNATE IMMUNITY AND POST-
TRANSPLANT LIVER INFECTION
Toll-like receptors 
Biology: Toll-like receptors (TLRs) are a family of  trans-
membrane proteins composed of  a leucine-rich extracel-
lular domain (the ligand binding site), a transmembrane 
domain, and a cytoplasmic domain [referred to as the 
TLR and interleukin (IL)-1 receptor (TIR) domain]. 
Binding of  a PAMP to a TLR triggers a signaling cascade 
that ultimately induces the production of  proinflamma-
tory cytokines and type Ⅰ interferons (IFNs). To date, 11 
TLRs are described in mammals. Each TLR recognizes 
different pathogenic structures, and are expressed on the 
cell surface (e.g., TLR1, TLR2, TLR4-6 and TLR10) or 
in endosomal compartments (e.g., TLR3 and TLR7-9). 
When PAMPs are detected, TLR dimerization and re-
cruitment of  intracellular adaptor proteins and kinases 
occur. Most TLRs use myeloid differentiation primary 
response protein (MyD88) as the signal adapter, while 
TLR3 uses TIR-domain-containing adapter-inducing 
IFN-β (TRIF)[23,24,37]. 
TLR1 is associated with TLR2, and both recognize 
the microbial lipopeptides present in a wide variety of  
bacteria, fungi, parasites and viruses. To date, 17 poly-
morphisms have been described in the coding region, of  
which ten are non-synonymous, that is, they produce an 
amino acid change[38]. Some of  these variants cause an 
inability of  TLR1 to bind its agonist without diminishing 
its expression[39], while others result in reduced protein 
expression in the cell wall without reducing intracellular 
levels, suggesting an alteration of  receptor trafficking[40]. 
In other cases, the polymorphism is associated with an 
excessive response that is partially mediated by increased 
cell surface expression of  TLR1[41]. 
TLR2 recognizes microbial membrane constituents 
such as lipoteichoic acid, peptidoglycan, and lipopro-
teins of  Gram-positive bacteria, lipoarabinomannan of  
Mycobacteria, and zymosan of  Candida, among others. 
TLR2 needs to form heterodimers with TLR1 or TLR6 
to be able to initiate cell activation. TLR2 sequencing 
has revealed multiple SNPs, although only a few are 
functionally relevant. The most frequently studied are 
Arg753Gln, Pro631His and Arg677Trp. The prevalence 
of  these polymorphisms varies by ethnicity[42]. The Arg-
753Gln polymorphism limits antigen recognition through 
deficient tyrosine phosphorylation rather than reducing 
protein expression, which impairs MyD88 recruitment, 
compromising TLR2-TLR6 assembly, and resulting in 
hyporesponsiveness to the antigen[43-48]. Defective mem-
brane internalization and functional gain of  the receptor 
has been observed with the Pro631His polymorphism, 
leading to increased immune activation[49]. 
TLR3 is an intracellular receptor located in the en-
doplasmic reticulum that typically recognizes double-
stranded RNA of  viral origin. After recognition of  its 
ligand, TLR3 interacts with UNC-93B, a protein required 
for TLR3 trafficking from endoplasmic reticulum to the 
endosomal compartment[50]. At least 136 SNPs exist in 
the TLR3, of  which only four exist in the protein-coding 
region and result in amino acid changes (N284I, Y307D, 
L412F and S737T). L412F is the most prevalent vari-
ant and reduces the receptor activity to near 30%, while 
Y307D and S737T have similar activity levels to the wild-
type alleles, and N284I reduces the activity to background 
levels. These variants do not lead to a reduction in the in-
tracellular protein expression or in vesicles, but do appear 
to alter the receptor trafficking to the cell surface[51,52].
TLR4 binds Gram-negative bacteria lipopolysac-
charide (LPS), fungal mannans, and certain viral glyco-
proteins. First, LPS is bound by circulating LPS-binding 
protein (LBP), which functions as an opsonin for CD14, 
which in turn acts as a catalyst for the binding of  LPS 
to MD-2, a co-receptor that is physically associated with 
TLR4. Finally, LPS binding to the TLR4/MD-2 complex 
activates intracellular signals that lead to the production 
of  proinflammatory cytokines. Although various non-
synonymous polymorphisms exist, only Asp299Gly and 
Thr399Ile are present at a frequency higher than 5%. 
They are located in the extracellular domain and, in Eu-
rope, frequently co-segregate[53]. Reduced responsiveness 
to LPS is higher in patients carrying the Asp299Gly poly-
morphism than in those with Thr399Ile. Some authors 
have demonstrated that hyporesponsiveness of  TLR4 
variants is associated with a structural change in the 
ligand-binding receptor and a deficient recruitment of  
MyD88 and TRIF signalling adapters, but not with either 
decreased TLR4 expression or the interaction with MD-2 
co-receptor[54,55]. 
TLR5 recognizes the flagellin of  flagellated bacte-
ria; of  the 18 SNPs described, 13 are non-synonymous, 
and three reduce the functional response to bacterial 
flagellin. These variants are Asp694Gly, Leu822Phe and 
Arg392stop, but only the latter is present in > 10% of  
individuals. Arg392stop causes the loss of  the transmem-
brane domain and the signaling of  the entire cytoplasmic 
tail. TLR5 polymorphisms are associated with Legionella 
pneumophila infection and Crohn’s disease[56,57].
TLR6 has a high sequence similarity to TLR1, and 
acts as a co-receptor with TLR2 that recognizes diac-
ylated lipopeptides. However, information on TLR6 
polymorphisms is limited. Although 53 SNPs have been 
described, only 11 encode for changes in amino acid se-
quences, and only one has an allelic frequency > 5% (Ser-
249Pro)[58]. The Ser249Pro polymorphism is associated 
with reduced IL-6 production in response to lipopeptide 
and mycobacterial stimulation. Although the mechanism 
by which this variant impairs IL-6 production is un-
known, it seems that it is not associated with a reduction 
in protein expression levels[59]. 
TLR7 and TLR8, which share a high degree of  struc-
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there are discordant results on the influence of  TLR4 
variants on Gram-negative bacterial infections. This is 
a research topic that warrants future investigation with 
larger cohort of  patients. 
Infections caused by Gram-positive bacteria are also 
important after liver transplantation[4]. Structural com-
ponents of  Gram-positive microorganisms are predomi-
nantly recognized by TLR2. Polymorphism of  TLR2 was 
first described following the observation of  an increased 
risk of  Gram-positive septic shock in patients admitted to 
the ICU with the genetic variant[77]. A study performed in 
755 liver transplant recipients demonstrated that the Arg-
753Gln TLR2 polymorphism was not associated with an 
increased incidence of  Gram-positive bacterial infections, 
although patients carrying the variant gene did present 
more frequently with septic shock and higher recurrence 
rates[78]. Despite this, the 90-d mortality was similar be-
tween patients carrying the variant and wild-type alleles. 
Other studies have also reported that TLR polymor-
phisms are associated not with a higher incidence of  
infectious disease but with a more severe presentation. 
Specifically, individuals with sepsis and septic shock car-
rying TLR1 variants have greater acute lung injury, organ 
dysfunction, and mortality, as well as a higher susceptibil-
ity to Gram-positive infection[41,79]. 
Solid organ transplant recipients are at higher risk of  
developing tuberculosis after transplantation, mostly by 
the reactivation of  latent infection[80]. TLRs, specifically 
TLR2 (associated with TLR1 and TLR6), TLR4, and 
TLR9 play critical roles in recognizing mycobacteria[81]. 
Some studies have described an association between 
some of  these polymorphisms and tuberculosis, although 
none are reported in liver transplant recipients. It is im-
portant to note that some TLR variants can be protective 
against mycobacterial infection[82]. 
TLR polymorphisms and viral infection after liver 
transplantation: The TLR2/TLR1 complex recognizes 
CMV envelope glycoproteins B and H, and associations 
between CMV infection and specific TLR SNPs have 
been described[46,83,84]. Kijpittayarit et al[85] studied the Arg-
753Gln TLR2 polymorphism in 92 HCV-infected liver 
transplant recipients, and observed that recipients carry-
ing the variant allele had higher CMV DNA levels in their 
peripheral blood when compared with recipients carrying 
the wild-type allele. Regardless of  the higher CMV rep-
lication in patients carrying the TLR2 variant allele, only 
homozygous patients presented CMV disease more fre-
quently. In a later study of  737 liver recipients published 
by the same group, an analysis of  the association between 
TLR2 polymorphisms and CMV infection revealed that 
homozygous Arg753Gln was significantly associated with 
an increased risk of  CMV disease, particularly tissue-
invasive forms[86]. 
Other viral infections have also been related to de-
ficiencies of  innate immunity, but no studies were per-
formed in liver transplant recipients. The herpes viruses 
are known to be recognized by TLR2, TLR9 and TLR3. 
tural similarity, are located in the endosomal compart-
ment membranes, and recognize single-stranded RNA. 
TLR7 is mostly expressed in plasmocytoid dendritic 
cells, while TLR8 expresses predominantly in monocytes, 
macrophages, and myeloid dendritic cells. They facilitate 
the production of  type Ⅰ IFN and other cytokines. Little 
is known about TLR7 and TLR8 polymorphisms. The 
Leu11Gln variant of  TLR7 is the most prevalent, and 
impairs the signaling sequence. It has been associated 
with HIV, a higher susceptibility to HCV infection, and a 
lower response to IFN treatment[60-62]. The Met1Val poly-
morphism of TLR8 leads to the formation of  a truncated 
form of  TLR8 that alters transcriptional activity. This 
variant has been associated with HIV and tuberculosis, 
and recent studies have shown an association of  TLR8 
polymorphisms with HCV infection[63]. 
TLR9 is located in the endoplasmic reticulum where 
it detects bacterial and viral nucleic acids containing CpG 
motifs. At least 50 SNPs have been described, but most 
occur infrequently. Some of  these variants are associated 
with noninfectious diseases such as lymphoma, asthma, 
and Crohn’s disease[64,65], as well as infections such as HIV, 
malaria, bacterial meningitis, and tuberculosis[66-70]. 
TLR 10 and 11 have not been studied in depth. 
TLR10 is a member of  the TLR1/2/6/10 cluster, and 
is hypothesized to have a similar function to TLR1 and 
TLR6, although the literature is scarce[49]. TLR11, which 
binds and recognizes uropathogenic bacteria, is probably 
nonfunctional in humans owing to a premature stop co-
don[53].
TLR polymorphisms and bacterial infection after 
liver transplantation: In a recent study that analyzed the 
genetic variants of  a broad number of  innate immune 
receptors in liver transplant recipients, including all TLR 
members, the authors found no association between ge-
netic variants and clinically significant bacterial infections 
during the first 3 mo after transplantation[71]. 
The authors of  a study of  706 liver recipients with 
TLR4 polymorphisms failed to find an association be-
tween the Asp299Gly and Thr399Ile variants and either 
the incidence or outcome of  Gram-negative infection; 
additionally, they noted that none of  patients with TLR4 
variants developed septic shock[72]. Furthermore, TLR4 
variants were not associated with bacterial infections 
after either kidney or simultaneous kidney and pancreas 
transplantation[73]. These results contrast with previous 
published studies in immunosuppressed and immuno-
competent patients. Lorenz et al[74] reported that patients 
admitted to intensive care units (ICUs) with septic shock, 
who carried the Asp299Gly TLR4 polymorphism, were 
more likely to have Gram-negative infections and more 
severe disease. Agnese et al[75] also observed that, in pa-
tients admitted to a surgical ICU, those with TLR4 poly-
morphisms had a higher incidence of  Gram-negative 
infections. In the transplantation setting, Ducloux et al[76] 
reported a higher incidence of  bacterial infection in kid-
ney transplant recipients carrying the TLR4 variant. Thus, 
11119 August 28, 2014|Volume 20|Issue 32|WJG|www.wjgnet.com
Sanclemente G et al . Innate immunity polymorphisms and infections
11120 August 28, 2014|Volume 20|Issue 32|WJG|www.wjgnet.com
Table 1  Main published findings in the association of innate immune gene variants with the development of infections after liver 
transplantation





Donor MBL Incidence of CSI was 3.8-fold higher in the recipients of MBL variant livers Bowman et al[123]
Mutation in the donor MBL2 was associated with CSI (HR = 2.8, P = 0.02) Worthley et al[124]
Mutation in donor MBL2 was associated to CSI (HR = 2.58, 95%CI: 1.62-4.10) de Rooij et al[126]
Higher incidence of septic shock in recipients of a MBL2 variant liver 
(HR = 9.64, 95%CI: 2.59-36)
Cervera et al[127]
Donor ficolin Mutation of donor ficolin was associated to CSI (HR = 2.33, 95%CI: 1.36-4) de Rooij et al[126]
NOD2 NOD2 polymorphism was associated to CSI (HR = 2.0, P = 0.04) Janse et al[145]
Donor MASP Wild-type allele of MASP2 in the donor was associated to CSI 
(HR = 2.65, 95%CI: 1.22-5.73)
de Rooij et al[126]
TLR2 Patients with TLR2 polymorphism presented higher rates of Gram positive infection 
recurrence (27.8% vs 11.8%, P = 0.07) and gram positive septic shock 
(11.1% vs 1.2%, P = 0.047)
Lee et al[78]
Viral infections TLR2 CMV load was higher in patients with TLR2 polymorphism (P = 0.03)
CMV disease was higher in patients homozygous for the TLR2 polymorphism 
(HR = 1.91, 95%CI: 0.91-3.4)
Kijpittayarit et al[85]
TLR2 polymorphism homozygosity was associated to tissue-invasive CMV disease 
(HR = 3.40, 95%CI: 1.51-7.64)
Kang et al[86]
MBL MBL wild-type genotype was associated to a higher incidence of CMV invasive 
disease in SOT (OR = 6.0, 95%CI: 1.1-32.5)
Cervera et al[129]
MBL deficient donor is associated to CMV infection (54% vs 32%, P = 0.02) de Rooij et al[130]
Ficolin 44% CMV infection in patients receiving a FNC2 wild-type liver vs 27% in patients 
receiving a variant FCN2 liver (P < 0.02)
de Rooij et al[130]
Fungal infections No studies in liver 
transplantation
   HCV recurrence TLR2 Homozygous TLR2 mutation is associated with allograft failure and mortality in 
HCV-infected recipients (RR = 5.2, 95%CI: 1.65-13.9)
Eid et al[155] 
TLR3 Higher rate of allograft failure and mortality in patients with TLR3 polymorphism 
(44.3% vs 30.8%, P = 0.09) 
Lee et al[156]
HCV patients with rapid fibrosis progression had impaired TLR7/8-induced 
interferon response compared with patients with slow fibrosis progression (P = 0.039) 
and impaired TLR3 and TLR9 cytokine production (P = 0.008)
Howell et al[157]
NK cells Lack to antiviral response to HCV therapy associated to the absence of the activating 
NK receptor haplotype KIR2DS2 (P = 0.008). KIR2L3 haplotype has been correlated 
to recurrent allograft hepatitis (P = 0.04)
Nellore et al[151]
IL28B No difference in the frequencies of IL28B polymorphisms in patients with and 
without fibrosing cholestatic hepatitis
Duarte-Rojo et al[168]
Recipients with CC genotype or CT genotype had delayed time to HCV recurrence 
compared to TT (10.4 vs 6.7 mo, P = 0.002). Recipients with TT genotype had worse 
graft survival (42% vs 62%, P = 0.02)
Allam et al[162] 
Higher response to antiviral therapy for CC genotype compared to CT or TT (59% 
vs 25%, P = 0.002). Higher sustained virological response in patients with favorable 
donor and recipient genotypes (P < 0.01)
Coto-Llerena et al[161] 
Higher progression to cirrhosis (HR = 5.96, 95%CI: 1.29-27.6), liver-related death or 
re-transplantation among recipients with a CC genotype donor. 
Duarte-Rojo et al[167] 
IL28B genotype in the recipient is associated to severe HCV recurrence (OR = 4.27, 
P = 0.014). Allele IL28B T in the donor tend to have lower incidence of severe HCV 
recurrence (OR = 0.46, P = 0.19)
Cisneros et al[166]
Sustained viral response to HCV therapy was 100% if both donor and recipient were 
CC genotype, while it was only 25% if neither donor nor recipient had CC genotype 
(P = 0.025)
Firpi et al[163]
IL28B non-CC in the recipient had a higher risk of severe recurrent HCV (OR = 1.57, 
P < 0.05). IL28B CC in the donor was associated to higher risk of severe recurrent 
HCV ( OR = 7.02, P < 0.001)
Biggins et al[164]
   No association TLR None of a broad range of genetic variants in recipient and donor innate immunity 
receptors was associated to bacterial or fungal infections after liver transplantation. 
de Mare-Bredemeijer 
et al[71]
MBL The presence of donor MBL2 variant is not associated to a higher incidence of CSI (47% 
vs 36%, P = 0.19) 
Curvelo et al[125]
TLR4 Incidence of Gram-negative infection was not higher in patients with TLR4 mutations 
(13.5% vs 19.3% in patients with wild-type allele, P = 0.39)
Lee et al[72]
TLR2 Incidence of Gram-positive bacterial infection was not different related to TLR2 
polymorphism (31.6% vs 31.6%)
Lee et al[78]
NOD: Nucleotide-binding and oligomerization domain; TLR: Toll-like receptor; MBL: Mannose-binding lectin; CSI: Clinically significant infections; SOT: 
Solid organ transplant; MASP: MBL-associated serine proteases; NK: Natural killer; IL: Interleukin.
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TLR2 polymorphisms have been associated with a higher 
recurrence rate of  herpes simplex virus (HSV) type 2 
genital ulcers, and greater viral shedding in healthy indi-
viduals[87]. Recurrent herpes labialis also appears more 
frequent in individuals with a deficient TLR3 response, 
which is probably related to the L412F polymorphism[88]. 
In contrast, Svensson et al[89] observed that individu-
als with the same SNP had lower HSV2 infection rates. 
Varicella-zoster virus is also recognized by TLR2[90]. 
TLR polymorphisms and fungal infection after liver 
transplantation: TLR2, TLR4 and TLR9 reportedly me-
diate some aspects of  fungal recognition[91]. 
Invasive candidiasis: A study in mice observed that 
cytokine production in response to candidal infection was 
determined by TLR2, but that TLR4 also participated in 
the host defense by modulating chemokine synthesis and 
neutrophil recruitment[92]. Specifically, TLR2 has been 
observed to recognize phospholipomannan, while TLR4 
recognizes O-linked mannan. TLR9 recognizes Candida 
albicans DNA and induces cytokine production, but 
the role of  TLR9 in invasive candidiasis might only be 
secondary[93]. In a study performed in non-neutropenic 
patients, Van der Graaf et al[94] described that the pres-
ence of  the Asp299Gly and Thr399Ile TLR4 polymor-
phisms was associated with increased risk for candidal 
septicemia. Woehrle et al[95] studied the cytokine response 
in critically ill patients with septic shock and its relation-
ship with TLR2 polymorphisms. The authors found that 
patients with candidal septicemia in the presence of  the 
Arg753Gln TLR2 SNP had an attenuated cytokine pro-
duction when compared with patients with the wild-type 
allele. More recently, Plantinga et al[96] analyzed the SNPs 
related to TLR1, TLR2, TLR4, TLR6, TLR9, MyD88 and 
and another adaptor protein named TIRAP (Toll-inter-
leukin 1 receptor domain containing adaptor protein) in 
patients with candidal septicemia, and they only observed 
an increased susceptibility to candidemia in patients with 
TLR1 polymorphisms. No information exists about the 
risk of  candida infection and TLR polymorphisms fol-
lowing liver transplantation. 
Invasive aspergillosis: Initial in vitro studies observed 
TLR2 to be the critical receptor for Aspergillus spp. recog-
nition by the innate immune system[97], and that this was 
mediated by CD14. Subsequent studies have determined 
that TLR4 can also detect Aspergillus, but that this only 
induces cytokine production in response to Aspergillus 
conidia, and not to the hyphae that are responsible for 
tissue invasion[98-100]. More recently, TLR9 has been ob-
served to recognize Aspergillus DNA[101]. Studies in stem 
cell recipients have described an association between 
TLR polymorphisms and invasive aspergillosis. For ex-
ample, Bochud et al[102] analyzed TLR2, TLR3, TLR4 and 
TLR9 polymorphisms in 336 patients undergoing alloge-
neic hematopoietic stem-cell transplantation; of  whom, 
33 developed invasive aspergillosis. The authors found an 
association between donor TLR4 polymorphisms and a 
higher risk of  invasive aspergillosis. Recently, de Boer et 
al[103] described similar results in patients receiving allo-
geneic stem cell transplantation from donors with TLR4 
polymorphisms. TLR2 can recognize Aspergillus, and 
TLR2 ligand recognition usually occurs through heterodi-
meric association with TLR1 or TLR6. Therefore, Kesh 
et al[104] analyzed the association between TLR1 or TLR6 
polymorphisms and the incidence of  invasive aspergil-
losis in stem cell transplantation recipients, and identified 
that either the Arg80Thr TLR1 polymorphism or the 
combination of  TLR1 Asn248Ser and TLR6 Ser249Pro 
polymorphisms in the recipients were associated with in-
vasive aspergillosis. In the setting of  liver transplantation, 
no studies have analyzed the association of  TLR poly-
morphisms with the incidence of  invasive aspergillosis. 
Other invasive fungal infections: Pneumocystis jirovecii 
pneumonia is a potentially life-threatening pulmonary 
infection in immunocompromised patients. Its incidence 
has declined substantially with the use of  universal pro-
phylaxis[105]. The major host defense system against Pneu-
mocystis infection is adaptive immunity, in which CD4+ 
T cells are the most important. In TLR4-deficient mice 
infected with Pneumocystis, the authors observed that the 
number of  lung cysts did not differ between TLR4-
deficient and wild-type mice, but they did observe that 
the former had more lung destruction[106]. The authors 
concluded that TLR4 signaling was not protective against 
Pneumocystis infection, but was responsible for regulat-
ing inflammation after infection. Zhang et al[107] analyzed 
the role of  TLRs in the recognition of  Pneumocystis in a 
mouse model, revealing that cytokine production in al-
veolar macrophages was activated through recognition 
by TLR2, but not TLR4. In a subsequent study, they also 
reported that TLR2 was not involved in the phagocy-
tosis of  Pneumocystis, but that TLR2 deficient mice had 
increased microbial burden when compared with wild-
type mice[108]. A recent study in mice found that cytokine 
production in response to Pneumocystis infection was de-
pendent on MyD88, but that it was independent of  both 
TLR2 and TLR4[109]. In conclusion, it is not clear which 
receptors are involved in the recognition of  Pneumocystis. 
The incidence of  cryptococcal infection after liver 
transplantation is low, and usually occurs in the late 
post-transplant period because of  reactivation of  latent 
infection. Mortality increases when the central nervous 
system is involved. Additionally, liver transplantation is 
associated with a more severe presentation, higher risk of  
dissemination, and a poorer outcome than other trans-
plant types[110]. Host defence against Cryptococcus neoformans 
is mainly mediated by CD4+ T lymphocytes, while the 
MyD88 adaptor plays a critical role in the innate immune 
response against Cryptococcus. Recent studies demonstrate 
that TLR9 recognizes the DNA of  this fungal patho-
gen[111,112]. Previous studies have reported that, although 
glucuronoxylomannan is a ligand for TLR2 and TLR4, it 
seems that these receptors are dispensable for the defence 
against Cryptococcus. van der Graaf  et al[113] and Yauch et 
al[114] analyzed mononuclear cells from volunteers, and 
observed that individuals carrying the Asp299Gly TLR4 
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polymorphism did not develop increased tumor necrosis 
factor-α or IL-10 levels when their mononuclear cells 
were stimulated by Cr. neoformans. 
Mannose-binding lectin
Mannose-binding lectin (MBL) is a soluble C-type lectin 
that recognizes carbohydrates on the surface of  numer-
ous microorganisms, including N-acetylglucosamine 
D-mannose, N-acetyl mannosamine, and L-fucose. Al-
though it is primarily synthesized by the liver, small levels 
of  extrahepatic production have been described in the 
small intestine and testes, which represent about 1% of  
the total produced. MBL circulates as a serum protein, 
although an intracellular pool of  MBL exists. It consists 
of  a structural subunit composed of  three identical 
polypeptide chains forming a triple helix. Circulating 
MBL consists of  oligomers of  this subunit, with higher 
order oligomers (tetramers to hexamers) being the ef-
fective forms. Additionally, MBL-associated serine pro-
teases (MASPs) are present in the serum, of  which only 
MASP-2 effectively activates the complement cascade. 
MBL can facilitate microorganism phagocytosis through 
direct opsonization or triggering complement activation, 
but also cooperates with other PRRs[115,116]. The MBL 
gene (MBL2) is located at chromosome 10q11.2-21. 
There are five known polymorphic sites within the MBL2 
gene, all of  which decrease the amount of  circulating 
MBL. Two SNPs are situated in the MBL2 promoter 
region (H or L at -550 and Y or X at -221), and three are 
in exon 1, at codons 52 (allele D), 54 (allele B) and 57 
(allele C). These SNPs interfere with the formation of  
higher-order oligomers and cause decreased serum levels 
of  MBL. Variant alleles of  both codon 54 and 57 reduce 
the levels of  functionally viable MBL in the serum to ap-
proximately one-eighth that of  the wild-type phenotype. 
The variant allele at codon 52 encodes intermediate levels 
of  MBL, and the polymorphism in the promoter region 
also reduces the MBL levels[34,117]. 
The presence of  MBL variant alleles is associated with 
bacterial and viral infection in both immunosuppressed 
and immunocompetent patients. In some studies, variant 
alleles have resulted in more severe clinical infections. In 
contrast, intracellular infection appears to be more fre-
quent in individuals with high MBL levels, because of  the 
increased opsonization and phagocytosis. Low levels of  
MBL might mitigate the excessive complement-mediated 
damage found in inflammatory conditions that cause tis-
sue destruction[33,118-122]. 
In the liver transplantation setting, because MBL is 
mainly produced by the liver, serum MBL levels depend 
on the donor genotype after transplantation. Thus, re-
duced serum MBL levels are seen in recipients with the 
wild-type MBL2 genotype who receive a liver with an 
MBL2 variant genotype. Conversely, patients with an 
MBL2 variant genotype receiving a liver from a wild-
type donor, experience increased serum MBL levels after 
transplantation. These changes occur during the first 2 d 
after transplantation[123,124]. 
MBL2 polymorphisms and bacterial infection after 
liver transplantation: Although a recent study did not 
observe a higher incidence of  bacterial infection in re-
cipients of  MBL2 variant livers[125], several studies have 
described a higher frequency of  clinically significant bac-
terial infections in patients receiving livers from MBL2 
variant donors compared to patients receiving wild-type 
livers[123,124,126]. In addition, these studies observed that 
MBL2 polymorphisms in the recipient were not associat-
ed with increase rates of  infection. A study by our group 
found no association between MBL2-deficient livers and 
the incidence of  bacterial infection, but we did observe 
that recipients of  an MBL2 variant allograft had more se-
vere infection (more frequent septic shock, higher levels 
of  C-reactive protein, and higher creatinine levels)[127]. 
MBL2 polymorphisms and viral infection after liver 
transplantation: The first study relating CMV infection 
to MBL deficiency in transplantation involved 16 kidney 
recipients at high risk of  developing CMV infection (do-
nor positive/recipient negative). The authors observed 
that patients with low serum MBL levels had a higher 
incidence of  CMV infection[128]. The same results were 
obtained in a study of  kidney and pancreas recipients[86]. 
More recently, we determined that the presence of  a 
wild-type genotype was associated with a higher inci-
dence of  invasive CMV disease in recipients with positive 
CMV serology pre-transplantation. These results could 
be explained by the facilitation of  CMV phagocytosis in 
patients with higher serum MBL levels[129]. In liver trans-
plantation, de Rooij et al[130] described that patients receiv-
ing livers from MBL2 deficient donors had an increased 
risk of  CMV infection compared with those receiving a 
wild-type liver. 
MBL does not neutralize HSV1 and HSV2, which 
block the activation of  both the classical and alterna-
tive complement pathways through glycoprotein C[131]. 
Despite this, Seppänen et al[132] described that individuals 
with recurrent HSV2 infection presented the MBL2 vari-
ant genotype more frequently.
MBL2 polymorphisms and fungal infection after liver 
transplantation: MBL binds to Aspergillus fumigatus, C. 
albicans, and Cr. neoformans[133]. There are no studies relat-
ing MBL2 polymorphisms with the incidence of  fungal 
infection in liver transplant recipients, but some studies 
have described associations in other immunosuppressed 
patients. For example, Granell et al[134] observed that do-
nor with an MBL-low genotype resulted in more invasive 
fungal infections in HLA-identical allogeneic stem cell 
transplantation recipients. Lambourne et al[135] reported 
that immunocompromised patients with lower MBL levels 
had a higher incidence of  invasive aspergillosis. Ou et al[136] 
reported a higher incidence of  cryptococcal meningitis in 
non-HIV patients with MBL2 polymorphisms. Addition-
ally, in nonimmunosuppressed patients with secondary 
peritonitis, candidal infection was more frequent in those 
with low MBL levels[137].
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As stated, MBL is associated with MASPs. When 
MBL recognizes a ligand, one of  three MASPs is acti-
vated. Of  these, MASP-2 plays a predominant role in 
complement activation. The MASP2 gene is located on 
chromosome 1p36.23-31, where nine polymorphisms 
have been identified[138-140]. de Rooij et al[126] observed that 
MASP2 polymorphism homozygosity in the donor was 
associated with an increased incidence of  clinically signif-
icant bacterial infections in liver transplant recipients. In 
stem cell transplantation, Granell et al[134] described that 
MASP2 mutations in the recipient were associated with 
higher incidences of  invasive fungal infection. 
Other PRRs
L-ficolin binds to carbohydrate present in lipoteichoic 
acid, a constituent of  Gram-positive bacteria[141]. Similar 
to MBL, the liver synthesizes ficolin, and polymorphisms 
in the promoter region of  the FCN2 gene are associated 
with differences in ficolin-2 serum levels. Patients receiv-
ing a donor liver with FCN2 polymorphisms had dem-
onstrated an increased incidence of  clinically significant 
bacterial infection[126]. Liver recipients of  donors without 
the minor T-allele of  the FCN2 gene present a higher 
incidence of  CMV infection compared with patients 
receiving a liver with at least one copy of  the minor T 
allele. The presence of  an FCN2 variant in the recipient 
does not increase the incidence of  CMV infection[130]. Re-
cently ficolin-A has been demonstrated to bind Aspergillus 
conidia, but there are no studies relating ficolin deficiency 
with invasive fungal infections in liver transplant recipi-
ents[142].
Nucleotide-binding and oligomerization domain 
(NOD)-like receptors (NLRs) are a family of  intracel-
lular receptors that recognize bacterial peptidoglycans. 
They are expressed by macrophages, dendritic cells and 
certain intestinal epithelial cells. NLR subfamilies include 
the NOD receptors (NOD1 and NOD2). Three NOD2 
SNPs have been described, and the variants have been 
associated with inflammatory disease such as arthritis, 
asthma, and Crohn’s disease[143,144]. Furthermore, a recent 
study has described a higher incidence of  bacterial infec-
tion in liver transplant recipients carrying the R720W 
polymorphism[145]. The authors also observed that homo-
zygous recipients for this polymorphism developed ear-
lier infection than heterozygous or wild type. However, 
this result has to be interpreted with caution given the 
small number of  patients.
Dectin-1 is a C-type lectin receptor expressed pre-
dominantly in the lungs and intestine by dendritic cells, 
monocytes, macrophages, neutrophils, a subset of  T cells, 
B cells, eosinophils, and mast cells. It is the main receptor 
involved in the recognition of  β-glucans, major structural 
components of  the fungal cell wall, and interacts with 
Candida, Aspergillus, Pneumocystis, Coccidioides, Penicillium, 
and Saccharomyces[98,146,147]. Ferwerda et al[148] first described 
an association between the Dectin-1 polymorphism and 
a higher incidence of  mucocutaneous fungal infection. In 
a recent study with hematology patients, a Dectin-1 poly-
morphism was associated with increased risk of  invasive 
aspergillosis and higher levels of  galactomannan[149]. In 
contrast, Rosentul et al[150] found no association between 
Dectin-1 polymorphisms and higher incidences of  candi-
demia or worse clinical outcomes. 
INNATE IMMUNITY AND HCV 
RECURRENCE
HCV infection is the most frequent cause of  end-stage 
liver failure requiring transplantation. After transplanta-
tion, HCV recurrence occurs in nearly all patients and 
the progression to cirrhosis and allograft failure is often 
accelerated. Between 10% and 30% of  liver recipients 
develop allograft cirrhosis within 5 years of  transplanta-
tion[151,152]. Risk factors associated with an accelerated 
progression to cirrhosis include: high HCV RNA load, 
genotypes 1b and 4 (probably related to the lower re-
sponse to antiviral treatment), female gender, older donor 
age, steatosis of  the graft, the degree of  HLA matching, 
the immunosuppressive drugs used, and CMV and hu-
man herpesvirus 6 infection after transplantation[153,154]. 
However, genetic factors may also play an important role 
in HCV recurrence and subsequent graft loss. 
In a study performed in 92 HCV-infected, liver trans-
plant recipients, the authors analyzed the relationship 
of  TLR2 Arg753Gln, TLR4 Asp299Gly and Thr399Ile 
polymorphisms with HCV recurrence, liver fibrosis, and 
mortality. They described a higher incidence of  allograft 
failure and mortality due to recurrence of  HCV infection 
in individuals homozygous for the TLR2 polymorphism, 
but not in either the TLR2 heterozygous patients or those 
with TLR4 variants[155]. The same team recently described 
that TLR2-deficient cells were unable to respond to HCV 
core and NS3 proteins in vitro, because the interaction 
between TLR2 and the intracellular MyD88 adapter was 
defective[47].
In a study analyzing the relationship between the 
Phe412Leu TLR3 polymorphism and HCV infection in 
liver transplant recipients, the TLR3 polymorphism oc-
curred more frequently in HCV-infected liver transplant 
recipients than in recipients for other indications. Uni-
variate analysis uncovered a higher incidence of  allograft 
loss and mortality in HCV-infected patients with the 
TLR3 polymorphism when compared with the wild-type 
genotype, although this association was lost following 
multivariate analysis[156]. Howell et al[157] recently analyzed 
several TLR polymorphisms and their relation with 
rapid fibrosis after liver transplantation in HCV infected 
patients. They concluded that patients who developed 
fibrosis earlier after transplantation were more likely to 
have deficient TLR7/8 and TLR3 responses.
Variants in NK cell receptors are also associated with 
the risk of  HCV recurrence after liver transplantation. 
Serum NK cell levels prior to transplantation may predict 
the severity of  HCV recurrence[151].
Although previous studies have described associa-
tions between HCV recurrence and distinct innate recep-
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tors, most have found a clear relation with the IL-28B 
polymorphism. IL-28 comprises a family of  cytokines 
(type Ⅲ IFN) including IL-28A, IL-28B and IL-29. The 
IL-28B gene (IL28B) is located on chromosome 19, is 
composed of  six exons, and produces IFN-λ3, which 
regulates T regulatory cells and enhances cellular adaptive 
immunity[158,159]. Polymorphisms in this gene do not affect 
serum IL-28B transcript levels, and their impact on IL-
28B function remains unknown. IL-28B is produced by 
both bone-marrow-derived cells and hepatocytes. Thus, 
the interplay between donor and recipient genotypes is 
complex after liver transplantation. In nontransplanted 
patients infected with HCV, IL28B polymorphisms have 
been associated with a sustained virological response 
after antiviral treatment; predominantly in those patients 
infected with viral genotype 1. In addition, the existence 
of  CC genotype in the rs12979860 locus has been associ-
ated to spontaneous HCV clearance[160]. 
In the liver transplantation setting, various studies 
have analyzed IL28B polymorphisms, mainly rs12979860 
(alleles T and C) and rs8099917 (alleles T and G). Recipi-
ents with the IL28B rs12979860 TT genotype typically 
have early and more severe HCV recurrence, and a higher 
incidence of  graft loss. Non-CC recipients who received a 
liver from a CC donor had the highest risk of  developing 
severe HCV recurrence. Patients with CC genotype not 
only had less severe HCV recurrence, but also presented 
higher rates of  sustained viral response after antiviral 
treatment when compared with recipients with a different 
genotype. Although patients who received a liver from 
a CC donor have more risk of  severe HCV recurrence, 
they also have higher virological response rates than pa-
tients receiving a liver from a non-CC donor[8,161-167]. The 
rs8099917 IL28B polymorphism has also been studied 
in patients with liver transplantation, revealing that non-
TT recipients receiving a liver from TT donors had the 
highest risk for severe recurrence. The IL28B genotype 
had no effect on graft survival in liver recipients without 
HCV infection[164]. 
Some authors have tried to analyze the relation be-
tween IL28B polymorphisms and the development of  
fibrosing cholestatic hepatitis (a severe manifestation of  
recurrent HCV infection after liver transplantation). As 
this is an infrequent complication, the results must be in-
terpreted with caution. However, it seems that recipients 
with an unfavorable IL28B genotype tend to have more 
fibrosing cholestatic hepatitis, and that this complication 
is more frequent when the donor has a favourable IL28B 
genotype[168]. 
CONCLUSION
The innate immune system could play an important role 
in liver transplantation. The majority of  studies have 
demonstrated that SNPs of  the innate receptors are as-
sociated with higher infection rates after transplantation. 
The importance of  these results is in the possibility of  
establishing individualized risk profiles for each patient 
prior to transplantation and the development of  pro-
phylactic strategies after transplantation. Furthermore, if  
specific deficiencies can be proven to be associated with 
higher infection rates, it may be possible to use recom-
binant molecules (i.e., recombinant MBL) as therapeutic 
agents. Future studies on the association between innate 
immunity variations and the risk of  infection after liver 
transplantation are warranted.
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